Belgium· BE-AMP-SAM521226-00

Glivec 400 mg

A imatinib product containing imatinib mesilate, registered in Belgium by PI Pharma. The same ATC class is registered in 4 of our 19 countries.

ATC L01XE01

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedGlivec 400 mgATCL01XE01REGISTER NO.BE-AMP-SAM521226-00PACKS LISTED1CHECKEDSeptember 26, 2026

Where it is registered

Imatinib is registered in 4 of 19 countries.

Countries holding a registration under ATC L01XE01 (imatinib), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 3 of them publish a price we can compare per daily dose

Imatinib · ATC L01XE01

4 / 19 countries

  • Belgiumprice
  • Ireland
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Imatinib Mesilate
Manufacturer
PI Pharma
Country
Belgium (BE)
ATC code
L01XE01
ATC class
Imatinib
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    7721152

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

770 interactions on record for imatinib.

Graded by severity as the source publishes them — 114 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Imatinib · interactions on record

770 records

  • 114 severe
  • 518 moderate
  • 23 minor
  • 111 info

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • EliglustatA16AX10severe
  • LonafarnibA16AX20severe

4 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Imatinib in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All imatinib products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Imagerolan, Imatinib 1a Pharma
  • Bulgaria · Иматиниб Тева Фарма, Меаксин
  • Cyprus · Imarem, Imatinib Koanaa 100 Mg
  • Czechia · Imanivec, Imatinib Grindeks
  • Germany · Imanivec, Imatinib 1 A Pharma
  • Denmark · Bimatix, Imatinib "sandoz"
  • Estonia · Glipox, Imatinib Grindeks
  • Spain · Imatinib Cipla, Imatinib Farmalider
  • Finland · Bimatix, Imatinib Hexal
  • France · Imatinib Arrow Lab, Imatinib Bgr
  • United Kingdom (Northern Ireland) · Imatinib, Imatinib Amarox
  • Greece · Imatek, Imatinib Aenorasis
  • Croatia · Imakrebin, Meaxin
  • Hungary · Imaniver, Imatinib 1 A Pharma
  • Ireland · Imatinib Krka D.D., Imatinib Rowex
  • Iceland · Bimatix, Glivec
  • Italy · Imanivec, Imatinib Dr. Reddy’s
  • Liechtenstein · Glivec, Imatinib Accord
  • Lithuania · Glipox, Imatinib Grindeks
  • Luxembourg · Imatinib, Imatinib Eg
  • Latvia · Imatinib Grindeks, Imatinib Inteli
  • Malta · Imatinib Tad, Nibix
  • Netherlands · Bimatix, Imakrebin
  • Norway · Bimatix, Glivec
  • Poland · Imatenil, Meaxin
  • Portugal · Imatinib Aurobindo, Imatinib Aurovitas
  • Romania · Imakrebin, Imatinib Grindeks
  • Sweden · Bimatix, Imatinib Amarox
  • Slovenia · Meaxin
  • Slovakia · Imatinib Glenmark, Imatinib Grindeks

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f709f808-f8e4-4d2e-9007-1ed393dd066d
GET /v1/drugs/f709f808-f8e4-4d2e-9007-1ed393dd066d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Glivec 400 mg",
  "name_fr": "Glivec 400 mg",
  "name_nl": "Glivec 400 mg",
  "amp_code": "SAM521226-00",
  "strengths": [
    "478.0000",
    "478.0000",
    "400.0000",
    "400.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Imatinib Mesilate",
    "Imatinib"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Imatinib",
  "authorisation_numbers": [
    "1637PI0472F003"
  ]
}

See everything about imatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.